Global Lyme Disease Diagnostic Market Size (2024 - 2029)

The Lyme Disease Diagnostic Market is anticipated to experience substantial growth, driven by factors such as the increasing prevalence of Lyme disease, the emergence of new diagnostic tests, and supportive government initiatives. The market's expansion is further fueled by rising healthcare expenditures and the growing incidence of tick-borne diseases. Despite these positive trends, challenges such as a lack of awareness about the disease may hinder market growth. Overall, the market is poised for significant development over the forecast period.

Market Size of Global Lyme Disease Diagnostic Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
lyme disease diagnostic market
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Lyme Disease Diagnostic Market Analysis

The Lyme Disease Diagnostic Market is expected to register a CAGR of 5.5% during the forecast period (2022-2027).

The worldwide COVID-19 pandemic has eclipsed the attention of healthcare professionals, affecting all areas of health and diagnostics care. The crisis has had several indirect health effects as well. People with Lyme disease symptoms were asked to postpone their tests, as the coronavirus spread began to take over the world. Moreover, the common symptoms of Lyme and COVID-19 viruses often start with non-specific flu-like symptoms with fever, headache, and general achiness and fatigue, which made patients and medical experts more concerned about both infections in individuals. Thus, patients were suggested to diagnose with the available medical institutions helping to diagnose other diseases. Furthermore, rising incidences of new vector-borne diseases, growing government initiatives, and rising healthcare expenditure are some more factors that are fuelling the market growth.

The rise in prevalence of Lyme disease, favorable government towards healthcare facilities, and the emergence of new Lyme diagnostic tests are the main driving factors for this market. Moreover, the increasing number of cases of tick-borne diseases is also promoting the growth of the Lyme disease diagnostic market. For instance, in 2021, according to the Centre for Disease Control and Prevention number of cases of tick-borne diseases reported was 47,743, leading to the adoption of Lyme disease diagnostic tests. For another instance, in 2022 United States Fair Health Organization reported that Lyme disease has experienced notable growth in the United States over the past 15 years and, as a result, has become an illness of increasing national concern. The same source also quoted that in 2021, private insurance claim lines with Lyme disease diagnoses rose by 357 percent in rural areas and 65 percent in urban areas from the past decade. Although Lyme disease is treatable with antibiotics, some Lyme patients later develop conditions with long-term symptoms, such as fatigue, muscle, and joint pain, and cognitive issues. Such conditions have been linked to post-treatment Lyme disease syndrome, sometimes called chronic Lyme disease.

The growing government initiatives and preventive measures are another reason to drive this market. For instance, in 2022 an article titled, 'New laws seek to boost funding of Lyme disease research' reported that New York officials have boosted funding for Lyme disease and tick-borne illnesses under a new law signed by Gov. Kathy Hochul. The measures, approved with bipartisan support, will create a voluntary tax check-off box to fund education, research, and prevention of this disease in the region. But despite the high instances of Lyme and tick-borne illnesses, the number of cases is believed to be much higher because of inaccurate diagnostic testing. It takes effect immediately Lawmakers have called for additional funding to research these illnesses, which they say have fallen behind federal and state levels. Thus, such a preventive government is driving its growth.

Thus, due to aforesaid mentioned reasons, the market is expected to show significant growth over the forecast period. However, lack of awareness regarding the disease is the reason which may slow down the growth of the market over the forecast period.

Lyme Disease Diagnostic Industry Segmentation

As per the scope, the Lyme disease diagnostic market is concentrating on the emerging diagnostic technologies, and several types of diagnostic tests such as serological, lymphocytic transformation test, Urine Antigen Testing, and Immunofluorescent staining, and Nucleic acid test. The Lyme disease diagnostic market is segmented by Diagnostic Technology (Serological Test (ELISA, Western Blot), Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining, Nucleic acid Test), by End-Users (Hospital, Clinical Laboratories, Other End-Users) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Diagnostic Technology
Serological Test
ELISA
Western Blot
Lymphocytic Transformation Test
Urine Antigen Testing
Immunofluorescent Staining
Nucleic acid Test
By End User
Hospitals
Clinical Laboratories
Other End-Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Lyme Disease Diagnostic Market Size Summary

The Lyme disease diagnostic market is poised for significant growth, driven by the increasing prevalence of Lyme disease and the emergence of new diagnostic tests. The market is experiencing a surge in demand due to the rising number of tick-borne disease cases and favorable government initiatives supporting healthcare facilities. Despite the challenges posed by the COVID-19 pandemic, which temporarily diverted attention from Lyme disease diagnostics, the market is rebounding as healthcare systems adapt and prioritize the diagnosis of vector-borne diseases. The development and adoption of advanced diagnostic tests, such as serological tests, are further propelling market expansion, as these tests are crucial for detecting Lyme disease in its later stages when other tests may not be effective.

North America is expected to maintain a significant share of the global Lyme disease diagnostic market, attributed to the high prevalence of tick-borne diseases and robust healthcare infrastructure in the region. The market is characterized by technological advancements and increased healthcare expenditure, which are enhancing diagnostic capabilities. Key players in the market, including Abbott, Bio-Rad Laboratories, and T2 Biosystems, are actively expanding their diagnostic portfolios to improve detection accuracy. Regulatory approvals, such as the USFDA's clearance of the T2Lyme Panel, underscore the ongoing innovation in diagnostic technologies. These developments, coupled with government support for research and prevention, are anticipated to drive substantial market growth in the coming years.

Explore More

Global Lyme Disease Diagnostic Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in Prevalence of Lyme Disease

      2. 1.2.2 Favorable Government Towards Healthcare Facilities

      3. 1.2.3 Emergence of New Lyme Diagnostic Tests

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness Regarding the Disease

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Diagnostic Technology

      1. 2.1.1 Serological Test

        1. 2.1.1.1 ELISA

        2. 2.1.1.2 Western Blot

      2. 2.1.2 Lymphocytic Transformation Test

      3. 2.1.3 Urine Antigen Testing

      4. 2.1.4 Immunofluorescent Staining

      5. 2.1.5 Nucleic acid Test

    2. 2.2 By End User

      1. 2.2.1 Hospitals

      2. 2.2.2 Clinical Laboratories

        1. 2.2.2.1 Other End-Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Lyme Disease Diagnostic Market Size FAQs

The Global Lyme Disease Diagnostic Market is projected to register a CAGR of 5.5% during the forecast period (2024-2029)

T2 Biosystems, Inc, Bio-Rad Laboratories, Oxford Immunotec USA, Inc, ROCHE DIAGNOSTICS INTERNATIONAL LTD and Abbott are the major companies operating in the Global Lyme Disease Diagnostic Market.

Lyme Disease Diagnostic Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)